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Abstract
Objecti6es: To assess the mean duration of use of HRT in general practice and to identify determinants of the
duration of HRT use. Methods: A general population of 1689 women aged 45–60 years and enlisted in five group
practices of general practitioners were followed for 9 months to trace first HRT prescriptions. All 103 women who
were prescribed HRT were followed for a period of 2.25 years. Duration of HRT was assessed by using the data
provided on the dispensing of HRT. Possible determinants of duration of use, such as attitude towards menopause,
menopausal status and another six variables were measured by means of a questionnaire. Results: None of the 103
women received HRT for a preventive purpose; the main indication was menopausal complaints. More than 60% of
the women stopped their HRT within 6 months and only 8% of the women remained on HRT for more than 2 years.
The mean duration of use was 7 months. Determinants that significantly predicted the duration of HRT use were age,
attitude towards treatment of the menopause and the group practice. Conclusions: The mean duration of HRT use is
very short, despite the fact that the most prevalent indication is the alleviation of menopausal symptoms. Apparently,
Dutch women are presently unwilling to take HRT for longer periods. © 1998 Elsevier Science Ireland Ltd. All rights
reserved.
Keywords: Hormonal replacement therapy; General practice; Menopause; Dutch women
1. Introduction
In the USA the prescription of estrogens in
menopausal women more than doubled in the* Corresponding author.
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period 1960 to 1974. The positive attitude towards
postmenopausal estrogen use in this period is
reflected by publications like Wilson’s widely read
book ‘Feminine Forever’ in which estrogens were
strongly recommended [1]. In Sweden the con-
sumption even trebled between 1973 and 1977 [2].
A drop in the use of estrogens appeared in the
late 1970s. This was probably due to the commo-
tion about reports of a strong association between
estrogen replacement therapy and endometrial
cancer [3,4]. Consensus exists that, in addition to
estrogens, women with an intact uterus should be
given progestogens in order to prevent endome-
trial cancer [5]. As a consequence of the acclaimed
beneficial effects of hormone replacement therapy
(HRT) on osteoporosis and cardiovascular dis-
ease, a renewed interest in HRT has emerged
[6,7]. In recent years, however, conflicting data
became available concerning the risk of breast
cancer associated with these drugs [8].
Appropriate duration of HRT is about 1–2
years for the main indications for HRT, i.e. the
alleviation of vasomotor symptoms, and at least
3–5 years to prevent osteoporosis and cardiovas-
cular diseases [9–12]. The few studies that as-
sessed the duration of use of HRT after its
initiation, indicate that estrogens are stopped ear-
lier than the indication would require [13–15].
This has been attributed to the fear of cancer,
discomfort associated with the inherent with-
drawal bleedings or side effects such as breast
tenderness [16–19].
The aims of our study were (i) to assess the
duration of use of HRT in general practice and
(ii) to determine which variables predict the dura-
tion of HRT use.
2. Methods
2.1. Recruitment
This study is part of a larger study aimed at
assessing the relationships between climacteric,
well-being, women’s attitude towards menopause
and medical attention [20]. In short, from the
municipal authorities of Krimpen aan den IJssel,
a commuter suburb of Rotterdam with approxi-
mately 28000 inhabitants, names and addresses of
all 2729 women aged 45–60 years were obtained.
These women were all enlisted in one of the five
group practices of general practitioners in
Krimpen aan den IJssel. In May 1990 they were
sent a questionnaire; 1947 women responded (re-
sponse, 71.3%). A random sample (n55) was
taken of the non-respondents in order to evaluate
how representative the respondent group was.
They were approached by telephone and 52 par-
ticipated (response 95%). The comparison be-
tween respondents and non-respondents revealed
no statistically significant differences in age,
menopausal status, hysterectomy, estrogen ther-
apy, level of education, work outside the home or
medical attention.
To measure the incidence of first HRT prescrip-
tions (i.e. prescription for women who did not use
estrogen therapy within 6 months preceding the
questionnaire), dispensing data were provided by
the two pharmacies in Krimpen aan den IJssel.
Both pharmacies are computerised. The measure-
ment period lasted from 1 July 1990 until 1 April
1991. Of the 1947 women who returned the ques-
tionnaire, 220 women who had used estrogen
therapy in the 6 months preceding 1 July, and the
seven women who used progestogens without es-
trogens, were excluded. Further, 31 women could
not be traced in the pharmacies’ database. The
remaining 1689 women were included in the study
and followed for a period of 9 months to monitor
first HRT prescriptions. In total, 103 women (in-
cidence in 9 months, 6.2%) were prescribed HRT.
This cohort forms the basis of the present study.
These 103 women were followed, from the initia-
tion of HRT, for a period of 2.25 years.
The study received approval from the Medical
Ethical Committee of Erasmus University and
Academic Hospital Dijkzigt in Rotterdam.
2.2. Measurements
The duration of HRT use of the 103 women in
the cohort was assessed by using dispensing data
provided by the two local pharmacies. For each
HRT dispensing the expected final date of use was
computed. If the interval between the computed
final date and the date of the next dispensing of
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Table 1
Mean duration in months of the continuous use of hormonal replacement therapy according to type of application in general
practice
B6 months 6–12 months 12–18 months 18–24 months \24 months
21 4All women (n103) (%) 364 8
31 0 0Transcutaneous (n16) (%) 069
20 461 2Oral (n49) (%) 12
79Creams (n24) (%) 21 0 0 0
Tibolone (n14) (%) 793 0 0 0
HRT was less than 42 days, the use of HRT was
considered to be continuous, irrespective of a
possible change of estrogen application. If the
next dispensing occurred more than 42 days after
the computed final date of the previous dispens-
ing, the HRT prescription was considered to be
interrupted. The period of 42 days was chosen to
make sure that short-term beneficial effects would
have disappeared. If a next dispense occurred
before the computed final date of the previous
dispense, the overlapping time was counted only
once in the computation of the total period of
HRT prescriptions. Several variables that could
influence the duration of HRT use were mea-
sured. The indication for HRT was assessed retro-
spectively by asking the women’s general
practitioners about their reason for prescription,
with the assistance of the patient’s records.
Three attitude clusters towards menopause were
distinguished: two clusters encompass items
reflecting the idea that ‘menopause is advanta-
geous’ and ‘menopause is disadvantageous’, and
one cluster encompasses items reflecting the idea
that ‘menopause should be treated (medically)’.
The women were asked to rate their opinion on
all items on a scale from 1 (totally agree) to 5
(totally disagree). Per cluster mean scores were
computed.
To ascertain menopausal status according to
last menstrual bleeding, women were classified
into pre-, peri- and postmenopausal on the basis
of the menstrual history. Premenopausal women
had had a regular menstruation pattern in the
preceding 12 months. Women were classified as
perimenopausal if irregular cycles or amenorrhea
had developed in the 12 months prior to the
questionnaire. Women were categorised as post-
menopausal if the last menstrual bleeding oc-
curred at least 12 months previously. Women who
had undergone hysterectomy were categorised as
a separate group.
The methods used to measure the other vari-
ables, such as type of application, education, hys-
terectomy, use of contraceptive pill, smoking and
group practice are shown in Tables 1 and 2.
2.3. Data analysis
The attitude measurements were dichotomised
around the median. For each category of a possi-
ble determinant, the mean duration (in months) of
the prescription of HRT within a period of 2.25
years was computed. Whether the submeans dif-
fered significantly from each other was tested by
means of analysis of variance. All variables for
which these differences were significant at a PB
0.10 level were entered into a multiple regression
analysis, with the duration of HRT use as the
dependent variable.
3. Results
The indications for the prescription of HRT
were relatively short term, i.e. to relieve vasomo-
tor symptoms or menstruation disturbances. The
mean duration of use of hormone replacement
therapy of the 103 women was 7 months (stan-
dard deviation, 7.1; range, 0.5–27 months). Table
1 and Fig. 1 show the duration of use for all
women and for the women on different applica-
tions of HRT. Within 6 months, more than 60%
of the women stopped using HRT. After 2 years,
8% of the women were still using HRT. Tibolone,
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Fig. 1. The mean duration in months of the continuous use of HRT, according to the type of application (n103 women).
which does not provoke withdrawal bleedings,
showed the highest withdrawal rate within 6
months (93%), whereas these figures were 79, 69
and 61% for creams, transcutaneous and oral
applications (excluding tibolone), respectively.
Table 2 shows the association between several
other variables and the mean duration of HRT
use (in months). Three of these variables appear
to be significantly related to the duration of HRT
use. Women having a more positive attitude to-
wards treatment before the onset of HRT, used
HRT on average 3.4 months longer than women
with a more negative attitude. Older women
stayed on HRT shorter than younger women. The
mean duration of HRT use for women aged 45–
50, 50–55 and 55–60 years were 8.9, 6.0 and 4.4
months, respectively. The mean duration of HRT
appeared to vary, according to the group practice,
from 4.4 (group practice A) to 10.4 months
(group practice D). Postmenopausal women used
HRT for a somewhat shorter period than pre-
and perimenopausal women.
The multivariate regression analysis showed
that the group practice and the attitude cluster
‘The menopause should be treated’, but not age,
were independent predictors of the duration of
HRT use. Compared to practice group A, the
women in the other group practices B, C, D and
E used HRT 3.7, 3.0, 3.2 and 3.3 months longer,
respectively (these numbers represent regression
weights). For the attitude cluster, the 50% of
women having a more positive attitude towards
treatment of the menopause were used as the
reference category. Compared to these women,
the 50% of women having a more negative atti-
tude used HRT on average 3.1 months less.
4. Discussion
In this follow-up study of 103 women, who
started to use hormonal replacement therapy
(HRT) in general practice, more than 60%
stopped their HRT within 6 months, and only 8%
of the women remained on HRT for more than 2
years. The mean duration of use was 7 months.
The main determinants of the duration of HRT
use were type of application of HRT, age group,
attitude towards treatment of the menopause be-
fore onset of HRT, and the women’s group
practice.
Few studies assessed the duration of use of
HRT. Wren and Brown found that, of 100
women, 61% continued therapy beyond 1 year
[14]. Barlow et al. found that, after 2 years, only
15% of the women were still on HRT [21]. We
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Table 2
Mean duration in months of use of HRT according to different characteristics
MeanDeterminant Standard deviation P value
Attitudes
Menopause is disadvantageous 0.14
6.1Below mediana 6.3
9.38.9Above medianb
Menopause is advantageous 0.76
8.5Below mediana 7.7
7.07.2Above medianb
Menopause should be treated 0.03
Below mediana 8.48.7
5.95.3Above medianb
Sociodemographic variables
Age group (years) 0.03
45–50 8.68.9
6.06.051–55
4.456–60 3.4
Education 0.78
7.46.6Low
6.7Middle 7.0
High 7.98.1
Gynaecological variables
Menopausal status according to last menstrual bleeding 0.10
Premenopausal 8.69.1
7.98.4Perimenopausal
5.0Postmenopausal 4.9
Hysterectomy 0.36
7.37.3No
5.8Yes 6.3
0.37Contraceptive pill
5.85.6Never used
Formerly used 7.37.2
Other variables
Smoking 0.61
6.36.3Never:ever
8.41–15 per day 9.3
\15 per day 7.4 8.1
0.05Group practice
4.5A 4.0
8.3B 9.3
6.15.8C
10.4D 10.0
5.0E 3.3
a Below median: 50% of the women who agree most with the items.
b Above median: 50% of the women who disagree most with the items.
found the same pattern, although the percentage
of women who stopped HRT is higher in our
study.
The majority of women in our study stopped
using HRT within 6 months. This indicates that
women take HRT for short-term effects, notably
to alleviate symptoms such as flushes. This was
confirmed by the women’s general practitioners.
Roberts reported that 80% of women use HRT
primarily to relieve menopausal symptoms, while
only 6% use it as a prophylactic against os-
teoporosis [22].
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If prevention of cardiovascular diseases and
osteoporotic fractures were to become more im-
portant indications, a longer use of HRT seems
likely.
Draper and Roland [23] suggested another im-
portant reason for early withdrawal from HRT:
they found that 50% of women judged the risks of
HRT higher than the benefits. Especially, the fear
of cancer may be crucial.
Tibolone, which does not provoke withdrawal
bleedings, showed the highest withdrawal rate
within 6 months (93%). It is somewhat surprising
that treatment which does not give withdrawal
bleeding is used for a shorter duration than regi-
mens that induce bleeding, since the study of
Do¨ren et al. on continuous combined HRT indi-
cates the opposite [24]. Therefore, we doubt
whether bleeding is the relevant factor.
Our study suggests that the role of the general
practitioner influences the duration of HRT use.
This is in accordance with the study of Ferguson
et al., who also found that the physician influ-
ences the duration of HRT use [25]. Doctors
probably vary in their opinion about the necessity
of chronic use of HRT, and thus influence their
patient’s behaviour [26,27].
The attitude towards treatment of the
menopause was a strong predictor of the duration
of HRT use. In an earlier study we established
that this attitude was also a predictor of the
initiation of HRT [28]. Sinclair et al. also reported
that a positive attitude towards treatment was
related to a longer duration of HRT use [29].
In a univariate analysis younger women seemed
to comply more with HRT use than older women.
Harris et al. also reported that menopausal
women who used estrogens were relatively young
[30]. Probably older women stop sooner when
they start a particular treatment (in the case of
alleviation of complaints) at a later age, when
complaints can be supposed to have disappeared
sooner as well. However, when multivariate anal-
ysis is used, the effect of age is no longer statisti-
cally significant, whereas the effects of group
practice and a positive attitude about treatment of
the menopause remain.
A disadvantage of our study is that we did not
measure the reasons for stopping HRT. Another
limitation lies in the fact that we evaluated the
indication retrospectively, using both the patients’
records and information from the general practi-
tioners. Further, the relatively small sample size
and the heterogeneity of HRT use (creams,
tablets, transdermal) limits the possibility to study
a wide variety of potential determinants of dura-
tion of HRT use, such as hysterectomy or
menopausal status.
An advantage of our pragmatic study concerns
the opportunity to observe duration and determi-
nants of use as it occurs in daily medical practice.
We conclude that the mean duration of HRT
use is short, despite the fact that the main indica-
tion was alleviation of menopausal symptoms.
Apparently, Dutch women are presently unwilling
to take HRT for longer periods.
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